alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
##### 



Exhibit 32.1 Certification of the Chief Executive Officer
Pursuant to 18 U.S.C. Section 1350,
As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 In connection with the Quarterly Report of Accenture SCA (the Company) on Form 10-Q for the
period ended May 31, 2005 as filed with the Securities and Exchange Commission on the date hereof
(the Report), I, William D. Green, Chief Executive Officer of Accenture Ltd, the general partner
of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, that:  (1)
    
    The Report fully complies with the requirements of Section 13(a) or 15(d) of the
Securities Exchange Act of 1934; and(2)
    
    The information contained in the Report fairly presents, in all material respects, the
financial condition and results of operations of the Company. Dated: July 11, 2005 /s/  William D. GreenWilliam D. GreenChief Executive Officer of Accenture Ltd,
General Partner of Accenture SCA
| EXHIBIT 99.1 |
|--------------|

| CERTIFICATION OF PERIODIC FINANACIAL REPORTS |
|----------------------------------------------|
| OF                                           |
| EXPRESSJET HOLDINGS, INC.                    |

I, James B. Ream, President and Chief Executive Officer of ExpressJet Holdings, Inc., certify, pursuant to Section 906 of theSarbanes-Oxley Act of 2002 (subsections (2) and (b) of Section 1350, Chapter 63 of Title 18, United States code), that:
| (1)   | the Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2003 (the “Periodic Report”) which thisstatement accompanies fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15U.S.C. 78m or 78o (d)) and |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (2)   | information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results ofoperations of ExpressJet Holdings, Inc.                                                                                                                  |

This certificate is being furnished solely for purposes of Section 906 and is not being filed as part of the PeriodicReport.
|  Date:  July 17,2003                 |                       | **/s/ James B.Ream                          ** |
|-------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                  | James B. Ream President and Chief Executive Officer                                                                            |

A signed original of this written statement required by Section 906 has been provided to ExpressJet Holdings, Inc. and will beretained by ExpressJet Holdings, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.
<PAGE>
                                                                    EXHIBIT 21.1

                              LIST OF SUBSIDIARIES

<Table>
<Caption>
Name                                                 State Formation
----                                                 ---------------
<S>                                                  <C>
AdvancePCS Holding Corporation                       Delaware

Consumer Health Interactive, Inc.                    Delaware

Baumel Eisner Neuromedical Institute, Inc.           Florida

AdvancePCS Mail Services of Birmingham, Inc.         Alabama

AdvancePCS Research, LLC                             Delaware
(dba - IMR)

HMN Health Services, Inc.                            Ohio

First Florida International Holdings, Inc.           Florida

Ambulatory Care Review Services, Inc.                Ohio

FFI Rx Managed Care, Inc.                            Florida

AdvancePCS SpecialtyRx, L.L.C.                       Delaware

AdvancePriority SpecialtyRx, L.L.C.                  Delaware

Dresing-Lierman, Inc.                                Ohio

TheraCom, Inc.                                       Ohio

AdvancePCS Health Systems, L.L.C.                    Delaware

ADVP Consolidation, L.L.C.                           Delaware

ADVP Management, L.P.                                Delaware

AdvanceRx.com, L.P.                                  Delaware

AdvancePCS Health, L.P.                              Delaware
(dba - IMR)

AdvancePCS Puerto Rico, Inc.                         British Virgin Islands

AFC Receivables Holding Corporation                  Delaware

Advance Funding Corporation                          Delaware
</Table>
[Federal Register Volume 89, Number 19 (Monday, January 29, 2024)]
[Notices]
[Page 5575]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-01607]


-----------------------------------------------------------------------

JUDICIAL CONFERENCE OF THE UNITED STATES


Advisory Committee on Evidence Rules; Meeting of the Judicial 
Conference

AGENCY: Judicial Conference of the United States.

ACTION: Advisory Committee on Evidence Rules; notice of open meeting.

-----------------------------------------------------------------------

SUMMARY: The Advisory Committee on Evidence Rules will hold a meeting 
in a hybrid format with remote attendance options on April 19, 2024 in 
Washington, DC. The meeting is open to the public for observation but 
not participation. An agenda and supporting materials will be posted at 
least 7 days in advance of the meeting at: https://www.uscourts.gov/rules-policies/records-and-archives-rules-committees/agenda-books.

DATES: April 19, 2024.

FOR FURTHER INFORMATION CONTACT: H. Thomas Byron III, Esq., Chief 
Counsel, Rules Committee Staff, Administrative Office of the U.S. 
Courts, Thurgood Marshall Federal Judiciary Building, One Columbus 
Circle NE, Suite 7-300, Washington, DC 20544, Phone (202) 502-1820, 
<a href="/cdn-cgi/l/email-protection#386a4d545d4b7b575555514c4c5d5d676b5d5b4a5d4c594a41785957164d4b5b574d4a4c4b165f574e"><span class="__cf_email__" data-cfemail="4c1e3920293f0f2321212538382929131f292f3e29382d3e350c2d2362393f2f23393e383f622b233a">[email protected]</span></a>.

(Authority: 28 U.S.C. 2073.)

    Dated: January 23, 2024.
Shelly L. Cox,
Management Analyst, Rules Committee Staff.
[FR Doc. 2024-01607 Filed 1-26-24; 8:45 am]
BILLING CODE 2210-55-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
Exhibit 10.11


 


Amendment 1 to Asset Transfer and
License Agreement


 


This first amendment
("Amendment 1") to the Asset Transfer and License Agreement by and between Revogenex Ireland Limited, an Irish
limited company ("Revogenex"), and Fortress Biotech, Inc. (f/k/a Coronado Biosciences, Inc.), a Delaware corporation
("Fortress")


dated as of February 17, 2015 (the "Agreement"),
is entered into as of June 23, 2016 , 2016. Fortress and Revogenex are both referred to herein as "Parties" or each individually, as a "Party."


 


WITNESSETH:


 


WHEREAS, pursuant to
the Agreement, Revogenex transferred the IND, and licensed the Product Intellectual Property, to Fortress, and Fortress will use
Commercially Reasonable Efforts to complete the Development of the Product and submit the NDA for the Product to the FDA for approval,
and thereafter commercialize, market and sell the Product in the Territory; and


 


WHEREAS, the Parties now wish to amend certain aspects
of the Agreement;


 


WHEREAS, the Parties
hereto agree that this Amendment 1 is hereby made an integral part of the Agreement, incorporated therein by this reference;


 


WHEREAS, capitalized
terms used herein and not otherwise defined shall have the respective meanings assigned to such terms in the Agreement;


 


NOW, THEREFORE, in
consideration of the premises contained herein and other valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the Parties hereto agree as follows:


 


		1.	Definition of "Territory". The definition of "Territory" is hereby deleted
in its entirety and made to read as follows:



 


"Territory" means worldwide; provided,
however, it shall not mean Central America


or South America with respect to 50mg and 100mg IV
Tramadol Hcl Injections.


 


		2.	Termination. Section 16.2(e) (Termination) is hereby deleted in its entirety and amended
to include the following termination provision:



 


(e) By
Revogenex if the NDA has not been filed within 54 months of the Effective Date and Coronado is in breach of Section 2.1 for failure
to use Commercially Reasonable Efforts to carry out all of the Product Development.


 


Except as amended
above, all other terms and conditions of the Agreement shall remain unchanged and in full force and effect.


 






     


     


    

 





IN WITNESS WHEREOF, the Parties hereto have
caused this Amendment 1 to be duly executed by their respective authorized representatives.


 


	Revogenex Ireland Limited	 	Fortress Biotech, Inc, Inc.
	 	 	 	 	 
	By:	/s/ Jeffrey H Ping	 	By:	/s/ Lucy Lu
	 	 	 	 	 
	By:	Jeffrey H Ping, PhD	 	By:	Lucy Lu
	 	 	 	 	 
	By:	Director	 	By:	EVP/CFO
	 	 	 	 	 
	By:	06/28/2016	 	By:	6/23/16
<PAGE>   1
                                  EXHIBIT 4.13

                         PROFESSIONAL SERVICES AGREEMENT


                    Between Registrant and K.B.Equities, Inc.



                                       
<PAGE>   2
                         PROFESSIONAL SERVICES AGREEMENT

      This Agreement memorializes an Agreement between Helionetics, Inc., with
its place of business at 6849 Hayvenhurst Avenue, Van Nuys, California 91406
(herein referred to as "Client") and KB Equities, Inc. with his\their place of
business at 541 Loring Ave Los Angeles, CA 90024 (herein referred to as
"Employee\Consultant") as through August 1996. In consideration of the mutual
covenants contained herein and other valuable consideration, the receipt and
adequacy of which is acknowledged, the parties do hereby agree as follows:

      I.    QUALIFICATION: The Employee has special skill and and experience in
            certain fields of activity in which the Client is interested.

      II.   SERVICES RENDERED: Client engaged the nonexclusive services of
            Employee in 1995\1996 and Employee rendered substantial services to
            Client over the period ended August 31,1996.

      III.  COMPENSATION: The Client issued to Employee an amount of 529,523
            restricted shares of the Client's common stock, in payment in full
            for the aforesaid services rendered through August 31, 1996. Per
            Attached Exhibit

      IV.   ENTIRE AGREEMENT: This document represents the complete agreement
            between the parties and may be modified or amended only by executed
            written agreements. This Agreement shall be construed in accordance
            with the laws of the State of California.

IN WITNESS WHEREOF: The parties hereto have duly executed this Agreement as of
the day and year noted above.

"Client"                                  "Consultant"
HELIONETICS, INC.



By:/s/ E. MAXWELL MALONE                       /s/ BERNARD B. KATZ
   -------------------------             --------------------------------
   E. Maxwell Malone                     KB Equities
   Chief Executive Officer
##### 



Exhibit 32.1
  Certification
    of the Chief Executive Officer
    Pursuant to 18 U.S.C. Section 1350,
    As Adopted Pursuant to Section 906 of the Sarbanes-Oxley
    Act of 2002
  Form 10-Q
  (1)
    The Report fully complies with the requirements of
    Section 13(a) or 15(d) of the Securities Exchange Act of
    1934; and(2)
    The information contained in the Report fairly presents, in all
    material respects, the financial condition and results of
    operations of the Company.    
          A signed original of this written statement required by
    Section 906, or other document authenticating,
    acknowledging, or otherwise adopting the signature that appears
    in typed form within the electronic version of this written
    statement required by Section 906, has been provided to the
    Company and will be retained by the Company and furnished to the
    Securities and Exchange Commission or its staff upon request.
EX-32.2

           Written Statement of the Chief Financial Officer and Chief
                 Executive Officer Pursuant to 18 U.S.C.  1350

Solely for the purposes of complying with 18 U.S.C. 1350, I,  the undersigned
Chief  Financial Officer of  McKenzie Bay International, Ltd.  (the "Company"),
hereby certify, based on  my  knowledge,  that  the Quarterly  Report  on Form
10-QSB of the Company  for  the  quarter ended  December 31, 2003  (the
"Report") fully complies  with  the requirements of Section 13(a) of the
Securities Exchange Act  of 1934   and  that  information  contained  in  the
Report  fairly presents,  in all material respects, the financial condition  and
results of operations of the Company.


Date: May 6, 2004

/s/ Gregory N. Bakeman
----------------------
Gregory N. Bakeman
Principal Executive Officer
## Martin,**Mic!1a~l** 

## (OST) From: 

### Sent: To: . ' ' . '"·. . .i . Margaret Mach <mjm99830@gmail.com> Tuesday, July 03, 2012 6:23 PM EAS (OST) ,·,. ,/ 

### Subject: . COMMENT ON EAS SERVICE AT KAKE, ALASKA DOT-OST-2008-0217 

### WE SUPPORT WINGS BECOMING THE CARRIER FOR KAKE- WE WEREHAPPY WITH THEM IN THE PAST AND HAVE ALWAYS HOPED THEY WOULD BECOME OUR AGENT HERE AGAIN.\ .•
« 

### MARGARET AND STUART MACH.



# .. J······..,)**c::~::.J**

0 N
#### UNITED STATES of America, Plaintiff-Appellee, v. Elias CONTRERAS, Defendant-Appellant.

No. 02-7693.

United States Court of Appeals, Fourth Circuit.

Submitted Feb. 6, 2003.

Decided Feb. 12, 2003.

*699Elias Contreras, Appellant Pro Se. Kevin Frank McDonald, Office of the United States Attorney, Greenville, South Carolina, for Appellee.

Before WILKINS, MICHAEL, and SHEDD, Circuit Judges.

Dismissed by unpublished PER CURIAM opinion.

PER CURIAM.

Elias Contreras, a federal prisoner, seeks to appeal the district court’s order denying relief on his motion filed under 28 U.S.C. § 2255 (2000). An appeal may not be taken from the final order in a § 2255 proceeding unless a circuit justice or judge issues a certifícate of appealability. 28 U.S.C. § 2258(c)(1) (2000). When, as here, a district court dismisses a § 2255 motion solely on procedural grounds, a certificate of appealability will not issue unless the movant can demonstrate both “(1) ‘that jurists of reason would find it debatable whether the [motion] states a valid claim of the denial of a constitutional right’ and (2) ‘that jurists of reason would find it debatable whether the district court was correct in its procedural ruling.’ ” *Rose v. Lee,*252 F.3d 676, 684 (4th Cir.) (quoting *Slack v. McDaniel,*529 U.S. 473, 484, 120 S.Ct. 1595, 146 L.Ed.2d 542 (2000)), *cert. denied,*534 U.S. 941, 122 S.Ct. 318, 151 L.Ed.2d 237 (2001). We have reviewed the record and conclude for the reasons stated by the district court that Contreras has not made the requisite showing. *See United States v. Contreras,*Nos. CR-99-209; CA-02-3201-6-20 (D.S.C. Oct. 3, 2002). Accordingly, we deny a certificate of appealability and dismiss the appeal. We dispense with oral argument because the facts and legal contentions are adequately presented in the materials before the court and argument would not aid the decisional process.

*DISMISSED.*
<PAGE>   1
EXHIBIT 11

                                  FURON COMPANY

                       COMPUTATION OF NET INCOME PER SHARE

<TABLE>
<CAPTION>
                                                                     YEARS ENDED
                                              ---------------------------------------------------------
                                                FEBRUARY 3,          JANUARY 28,         JANUARY 29,
                                                   1996                 1995                 1994
                                              ---------------------------------------------------------
<S>                                            <C>                  <C>                   <C>         
PRIMARY INCOME PER SHARE

Earnings
    Net income                                 $   13,169,000       $   11,438,000        $  8,170,000
                                               ==============       ==============        ============
Shares
    Weighted average number of common
    shares outstanding                              8,821,297            8,674,135           8,615,289

    Shares issuable from assumed exercise
     of stock options                                 218,965              318,791             243,911
                                               ---------------      --------------        ------------

    Average shares as adjusted                      9,040,262            8,992,926           8,859,200
                                               ==============       ==============        ============

Primary income per share                       $         1.46       $         1.27        $       0.92
                                               ==============       ==============        ============


FULLY DILUTED INCOME PER SHARE

Earnings
    Net income                                 $   13,169,000       $   11,438,000        $  8,170,000
                                               ==============       ==============        ============

Shares
    Weighted average number of common
    shares outstanding                              8,821,297            8,674,135           8,615,289

    Shares issuable from assumed exercise
    of stock options                                  220,961              443,300             243,911
                                               ---------------      --------------        ------------

    Average shares as adjusted
    for full dilution                               9,042,258            9,117,435           8,859,200
                                               ==============       ==============        ============

Fully diluted income per share                 $         1.46       $         1.25        $       0.92
                                               ==============       ==============        ============
</TABLE>

                                       50
UN PUBLISHED
UNITED STATES COURT OF APPEALS FOR THE FOURTH CIRCUIT

No. 19
- 6544

UNITED STATES OF AMERICA , Plaintiff

- Appellee ,

v. KENYATTE BROWN , Defendant

- Appellant

.

Appeal from the United States District Court for the District of South Carolina , at Columbia

. Margaret B. Seymour , Senior District Judge. ( 3:01

- cr
- 01109

- MBS

- 1 )

Submitted : November 21 , 2019 Decided: November 25, 2019

Before KEENAN and DIAZ , Circuit Judges , and SHEDD , Senior Circuit Judge

.

Affirmed by un published per curiam opinion

.
Emily Deck Harrill, Assistant Federal Public Defender, OFFICE OF THE FEDERAL PUBLIC DEFENDER, Columbia, South Carolina, for Appellant. Sherri A. Lydon, Unit ed States Attorney, William K. Witherspoon, Assistant United States Attorney, OFFICE OF THE UNITED STATES ATTORNEY, Columbia, South Carolina, for Appellee.
Unpublished opinions are not binding precedent in this circuit.2 PER CURIAM: Kenyatte Brown appea ls the district court’s order denying his motion for a sentence reduction pursuant to § 404 of the First Step Act, Pub. L. No. 115

- 391, 132 Stat. 5194, 5222 (2018), which permits a district court to impose a reduced sentence on a defendant
convicted of a c overed offense as if certain provisions of the Fair Sentencing Act of 2010,
Pub. L. No. 111

- 2220, 124 Stat. 2372, 2372 (2012), were in effect at the time the defendant
committed the covered offense. Section 404(b) of the First Step Act defines a covered

o ffense a s “a violation of a Federal criminal statute, the statutory penalties for which were modified by section 2 or 3 of the Fair Sentencing Act.” Brown was convicted of possessing with intent to distribute five grams or less of crack cocaine, in violat ion of 21 U.S.C. § 841(a)(1), (b)(1)( C ) (2012). Because the Fair Sentencing Act did not modify the statutory penalties for that offense, Brown’s offense is not a covered offense and the district court correctly denied Brown’s motion to reduce his sentence pursuant to § 404 of the First Step Act.
We therefore affirm the district court’s order. We dispense with oral argument because the facts and legal contentions are adequately pr esented in the materials before this court and argument would not aid the decisional process.
AFFIRMED
Exhibit 10.18


 


RESIGNATION


  


March
14, 2017


 


Board
of Directors


Therapix
Biosciences Ltd.


5
Azrieli Center (Square Tower) 27 Fl.


Tel-Aviv
Yafo, 6702501 Israel


 


Re:      Resignation


 


Ladies
and Gentlemen:


 


Please
accept my resignation as a director of Therapix Biosciences Ltd. (the “Company”), with such resignation to be effective
upon acceptance by the Board of Directors of the Company if the Company has not consummated a firm commitment underwritten offering
of American Depositary Shares (the “Offering”) on or prior to April 30, 2017.


 


For
the avoidance of doubt, this resignation letter shall have no force or effect if the Company consummates the Offering on or prior
to April 30, 2017.


 





	 	 	/s/ M. David Silverman
Michigan Supreme Court

Lansing, Michigan

Robert P. Young, Jr.

, Chief Justice

Michael F. Cavanagh

Stephen J. Markman

Mary Beth Kelly

Brian K. Zahra

Bridget M. McCormack

David F. Viviano

, Justices

I, Larry S. Royster , Clerk of the Michigan Supreme Court, certify that the

foregoing is a true and complete copy of the order entered at the direction of the Court.

April 28, 2014

t0421 

# Order

Clerk April 28, 2014

148604

SARAH DEMING,

Plaintiff

- Appellant

,

v SC: 148604

COA: 309989

Oakland CC: 2011

- 122030

- CZ

CH NOVI, L.L.C. d/b/a EMAGINE NOVI and

FILMDISTRICT DISTRIBUTION, L.L.C.,

Defendants

- Appellees.

_________________________________________/

On order of the Court, the application for leave to appeal the October 15, 2013

judgment of the Court of Appeals is considered, and it is DENIED, because we are not

persuaded that the questions presented should be reviewed by this Court.